775 results on '"Obara, Wataru"'
Search Results
152. Genomic features of renal cell carcinoma developed during end-stage renal disease and dialysis.
153. PD40-02 TIM3 EXPRESSION ON TUMOR CELLS PREDICTS RESPONSE TO ANTI-PD-1 THERAPY FOR RENAL CANCER
154. MP14-17 VALIDATION OF REMARCC MODEL FOR SELECTION OF CYTOREDUCTIVE NEPHRECTOMY IN PATIENTS WITH mRCC
155. PD55-04 EFFECT OF NEOADJUVANT CHEMOTHERAPY ON THE IMMUNE MICROENVIRONMENT IN MUSCLE INVASIVE BLADDER CANCER
156. MP15-18 RECONSTRUCTION OF THE RETZIUS SPACE BY PERITONEAL SUTURE FOLLOWING ROBOT-ASSISTED RADICAL PROSTATECTOMY IMPROVES POSTOPERATIVE URINARY INCONTINENCE
157. PD43-03 INDIVIDUALIZED MUTATION DETECTION IN PLASMA AND URINARY CIRCULATING TUMOR DNA FOR MONITORING UPPER TRACT UROTHELIAL CARCINOMA USING DIGITAL POLYMERASE CHAIN REACTION
158. Dysuria therapeutic agents as an independent prognostic factor for the primary recurrence of non-muscle invasive bladder cancer: a propensity score matching study
159. Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular-targeted therapy
160. Genome-wide association study identified SNP on 15q24 associated with bladder cancer risk in Japanese population
161. Third-generation three-dimensional display system for laparoscopic radical nephrectomy reduced surgical complications compared to a two-dimensional display system.
162. Outcomes of axitinib versus sunitinib as first‐line therapy to patients with metastatic renal cell carcinoma in the immune‐oncology era
163. Third-generation three-dimensional display system for laparoscopic radical nephrectomy reduced surgical complications compared to a two-dimensional display system
164. Phase I/II study to evaluate the efficacy of TAS0313, a cancer peptide vaccine, combined with pembrolizumab for locally advanced or metastatic urothelial carcinoma.
165. Additional file 1 of Improvement of three-dimensional motion sickness using a virtual reality simulator for robot-assisted surgery in undergraduate medical students: A prospective observational study
166. Additional file 2 of Improvement of three-dimensional motion sickness using a virtual reality simulator for robot-assisted surgery in undergraduate medical students: A prospective observational study
167. Outcomes of axitinib versus sunitinib as first-line therapy to patients with metastatic renal cell carcinoma in the immune-oncology era
168. Efficacy of Everolimus in Patients with Advanced Renal Cell Carcinoma Refractory or Intolerant to VEGFR-TKIs and Safety Compared with Prior VEGFR-TKI Treatment
169. ADJUVANT CANCER PEPTIDE VACCINE TREATMENT WITH INTRAVESICAL BCG THERAPY FOR NON-MUSCLE INVASIVE BLADDER CANCER: MP56-17
170. IMPACT OF POLYMORPHISMS IN ABCB1 AND NRI2 WITH DOCETAXEL RESPONSE FOR CASTRATION-RESISTANT PROSTATE CANCER: MP49-18
171. Outcome of Metastasectomy for Urothelial Carcinoma: A Multi-Institutional Retrospective Study in Japan
172. Relationship between miR‐155 expression and clear cell papillary renal cell carcinoma in the dialyzed kidney
173. Improvement of three-dimensional motion sickness using a virtual reality simulator for robot-assisted surgery in undergraduate medical students: a prospective observational study
174. The comparison of cytoreductive nephrectomy (CN) with tyrosine kinase inhibitor therapy alone in patients with primary metastatic renal cell carcinoma (mRCC).
175. Phase II open-label study of S-588410 as maintenance monotherapy after first-line platinum-containing chemotherapy in patients with advanced or metastatic urothelial carcinoma.
176. Identification and analysis of a novel NR0B1 mutation in late-onset adrenal hypoplasia congenita and hypogonadism
177. Additional file 1 of Plasma cytokine levels before and 1 year after successful living-donor renal transplantation
178. A Case of Renal Pelvic Cancer with Acquired Hemophilia and Leukemoid Reaction
179. Association of a single-nucleotide polymorphism in the immunoglobulin μ-binding protein 2 gene with immunoglobulin A nephropathy
180. TIM3 expression on tumor cells predicts response to anti-PD-1 therapy for renal cancer
181. Serum levels of cardiac troponin I and other marker proteins in patients with chronic renal failure
182. Impact of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma receiving systemic tyrosine kinase inhibitor therapy: A multicenter retrospective study
183. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
184. Association of single-nucleotide polymorphisms in the polymeric immunoglobulin receptor gene with immunoglobulin A nephropathy (IgAN) in Japanese patients
185. Neoadjuvant Gemcitabine Plus Carboplatin for Locally Advanced Bladder Cancer
186. Case of complete response to everolimus for metastatic renal cell carcinoma
187. Cancer Peptide Vaccine Therapy Developed from Oncoantigens Identified through Genome-wide Expression Profile Analysis for Bladder Cancer
188. Evidence-Based Clinical Practice Guideline for Renal Cell Carcinoma: The Japanese Urological Association 2011 update
189. A global atlas of genetic associations of 220 deep phenotypes
190. Complete Pathological Response to Neoadjuvant Pembrolizumab in a Patient With Chemoresistant Upper Urinary Tract Urothelial Carcinoma: A Case Report
191. A prospective study on the association between post-voiding residual volume and quality of life during bacille Calmette-Guérin (BCG) instillation therapy for non–muscle-invasive bladder cancer
192. Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favorable/Intermediate Risk: Multicenter Randomized Trial CROSS-J-RCC
193. Rapid progression of recurrent disease in a patient with renal cell carcinoma with vaginal metastasis
194. Large-scale genome-wide association study in a Japanese population identifies novel susceptibility loci across different diseases
195. Analyses of Nivolumab Exposure and Clinical Safety Between 3-mg/kg Dosing and 240-mg Flat Dosing in Asian Patients with Advanced Renal Cell Carcinoma in the Real-World Clinical Setting
196. Evaluation of a new measurement method of indoxyl sulfate in hemodialysis patients
197. Influence of unstable psychological condition on the quality of life of hemodialysis patients
198. Inflammatory markers for predicting responses to nivolumab in patients with metastatic renal cell carcinoma
199. MP31-14 CLINICAL SIGNIFICANCE OF HIGH URINARY SODIUM-TO-POTASSIUM RATIO IN PATIENTS WITH NOCTURNAL POLYURIA
200. Comprehensive analysis of somatic copy number alterations in clear cell renal cell carcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.